| Summary: | <p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 114%;" align="justify"><strong><span style="font-family: 'Times New Roman'; line-height: 114%;">Introduction:</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: Arial; line-height: 114%; font-size: 12,0000pt;"> Depression is a common psychiatric disorder leading to high burden especially for some other psychiatric comorbidity. Annually over 43 billion dollars are expended for patients with depression among them 28% are directly for depression and other costs are related to mortality and morbidity due to depression. </span></p><p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 114%;" align="justify"><strong><span style="font-family: 'Times New Roman'; line-height: 114%;">The aim of the study: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: Arial; line-height: 114%; font-size: 12,0000pt;">Paying attention to new options for treating depression – a disease that affects more and more people.</span></p><p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 114%;" align="justify"><strong><span style="font-family: 'Times New Roman'; line-height: 114%;">Material and method: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: Arial; line-height: 114%; font-size: 12,0000pt;">The research was done by the usage of the PubMed and Google Scholar articles about the topic of: botulinum toxin; depression; treatment.</span></p><p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 114%;" align="justify"><strong><span style="font-family: 'Times New Roman'; line-height: 114%;">Description of the state of knowledge: </span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: Arial; line-height: 114%; font-size: 12,0000pt;">Injecting Botox into the muscles responsible for expression of anguish or sadness may potentially decrease the patients experience of feelings. Botox reversibly blocks acetylcholine release from neuronal axons into the synapse, inhibiting neuromuscular transmission. If the facial feedback hypothesis is correct, by injecting Botox into the corrugator and procerus muscles, it will reversibly inhibit frown facial expressions and have the capability of propagating or enhancing sad and depressed feelings.</span></p><p class="MsoNormal" style="text-align: justify; text-justify: inter-ideograph; line-height: 114%;" align="justify"><strong><span style="font-family: 'Times New Roman'; line-height: 114%;">Summary</span></strong><span style="mso-spacerun: 'yes'; font-family: 'Times New Roman'; mso-fareast-font-family: Arial; line-height: 114%; font-size: 12,0000pt;">: The results from all randomized control trials proved that botulinum toxin A injection in the glabellar region was associated with significant improvement mood and may be a s</span><span style="font-family: 'Times New Roman'; line-height: 114%;">afe and effective treatment to reduce symptoms of depression.</span></p>
|
|---|